Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient by Massey, Thomas et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/97390/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Massey, Thomas, Smith, Rachel, Sadiq Shaheena, Shaheena, Overton, Christopher and Pearson,
Owen R. 2017. Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a
pregnant MS patient. Neurology 10.1212/WNL.0000000000003604 file 
Publishers page: http://dx.doi.org/10.1212/WNL.0000000000003604
<http://dx.doi.org/10.1212/WNL.0000000000003604>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Clinical/Scientific
Notes
Thomas H. Massey, MD,
DPhil
Rachel Smith, MD
Shaheena Sadiq, MD
Christopher Overton,
MD
Owen R. Pearson, MD
RESCUE OF SEVERE BRAIN AND CERVICAL
CORD IRIS BY RESTARTING NATALIZUMAB IN
A PREGNANT MS PATIENT
Natalizumab inhibits lymphocyte trafficking across
the blood–brain barrier, reducing relapse rates by
up to 70% in patients with relapsing-remitting mul-
tiple sclerosis (RRMS). Discontinuation of the drug,
usually due to pregnancy or risk of progressive mul-
tifocal leukoencephalopathy (PML), can trigger the
return of disease activity or, occasionally, a fulminant
immune reconstitution inflammatory syndrome
(IRIS) as lymphocytes re-enter the CNS.1–3
We describe a case of life-threatening IRIS follow-
ing natalizumab cessation in pregnancy, but complete
clinical rescue with no adverse sequelae following
drug restart in the second trimester.
Case report. A 21-year-old woman was diagnosed
with RRMS after 2 disabling relapses within 12
months (1 hemiparetic, 1 dorsal cord, each resolving
completely within 4 weeks without corticosteroids)
and brain MRI consistent with progressive, active
demyelination (figure, A.a–c, worst Expanded
Disability Status Scale [EDSS] score 3.0). Monthly IV
natalizumab (300 mg) was commenced (negative JC
virus [JCV] status) and the patient had no further
relapses in the next year (EDSS 1.0). She attended
clinic for her 15th infusion and reported that she was
8 weeks pregnant: natalizumab was discontinued. At 16
weeks’ gestation (3 months after her last natalizumab
infusion), the patient developed rapidly progressive
weakness of all 4 limbs over a week. She was
hospitalized but deteriorated further, becoming
encephalopathic and quadriparetic, with a complex
ophthalmoplegia and gross ataxia (EDSS 9.5;
bedbound and requiring all care). MRI revealed
multiple large new lesions within the cerebral white
matter, brainstem, and cerebellum, as well as
longitudinally extensive lesions throughout the cervical
cord (figure, A.d–h). Contrast was not administered due
to pregnancy. Lumbar puncture revealed normal
opening pressure and CSF constituents, zero cells,
and no microorganisms. Routine blood tests
(including anti–aquaporin 4) and urinalysis were nor-
mal. Treatment was commenced with acyclovir, IV
methylprednisolone (1 g/d for 3 days), and supportive
care. Fetal viability was confirmed by ultrasonography.
There was only modest improvement after 2
weeks (EDSS 8.0). PML was ruled out after negative
JCV PCR on CSF. Acyclovir was stopped following
a negative CSF viral PCR screen. EEG showed diffuse
encephalopathic changes but no seizure activity. Fol-
lowing further deterioration, a second course of IV
methylprednisolone (1 g/d for 5 days) was adminis-
tered but there was no improvement, the patient con-
tinuing to require 24-hour inpatient nursing care
(EDSS 9.5). Given the patient’s severe disability, we
restarted monthly natalizumab infusions at 24 weeks’
gestation, and continued enteral prednisolone. Over
the following 2 weeks, the patient’s neurologic con-
dition improved dramatically: her encephalopathy
lifted, muscle tone and power improved, and balance
returned. Further improvements over the next 4
months enabled her to regain independence and re-
turn to near baseline (EDSS 4.0; figure, B).
The patient gave birth to a healthy baby girl by elec-
tive cesarean section at 40 weeks’ gestation (birth-
weight 3,500 g; Apgar scores of 9 and 10). The
infant required phototherapy for mild neonatal jaun-
dice, but was otherwise well: there was no evidence of
hematologic disorders. Follow-up MRI postdelivery
showed reduced lesion load (figure). One year later,
the patient had improved further: her walking was
unimpaired, she had mild ataxia only (EDSS 2.0),
and her cognitive abilities had recovered to baseline
(Addenbrooke Cognitive Examination score 98/100).
She could care for her baby, and had re-entered regular
employment. Follow-up MRI of brain and cervical
cord showed further improvements (figure, A.m–q).
Discussion. This case illustrates a rare life-threatening
complication of stopping natalizumab in multiple
sclerosis: brain and cervical cord IRIS. Symptom onset
coincided with natalizumab washout, and recovery
was only seen after restarting treatment during
pregnancy. Data on IRIS treatment outside pregnancy
suggest that rescue therapy with natalizumab, as here,
is most efficacious. Corticosteroids are only moderately
beneficial, whereas removing natalizumab by plasma
exchange can worsen CNS inflammation.4 The
recovery observed here was rapid for various reasons:
(1) effective blockade of further lymphocyte access to
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology 1
 Published Ahead of Print on January 11, 2017 as 10.1212/WNL.0000000000003604
Figure MRI and disability status of the patient over time
(A) MRI of brain and cervical cord over time. All images are T2-weighted without contrast enhancement except A.g, A.l, and A.p, which are diffusion-weighted
(gradient factor b5 1,000 s/mm2). (A.a–A.c) Brain at diagnosis of multiple sclerosis (pre–natalizumab [NTZ]). (A.d–A.h) Brain and cervical cord at presentation
during pregnancy 3 months after cessation of NTZ. (A.i–A.l) Brain 6 months after restarting NTZ. (A.m–A.q) Brain and cervical cord 1 year after restarting
NTZ. (B) Bar chart of Expanded Disability Status Scale (EDSS) score against time with major events depicted. IVMP 5 IV methylprednisolone (course
number); RRMS 5 relapsing-remitting multiple sclerosis.
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the CNS by natalizumab [peak a4-integrin saturation
on lymphocytes is achieved 3 days after initial IV
infusion and maintained at .80% for 4 weeks,
sufficient to prevent significant CNS transmigration of
lymphocytes5,6]; (2) ongoing steroid treatment of CNS
inflammation; (3) effective endogenous remyelination
mechanisms in this patient (suggested by complete
and timely recovery from previous disabling relapses);
and (4) early resolution of encephalopathy enabling
effective therapy and accelerated recovery.
The decision to suspend or continue natalizumab
in pregnancy must consider risks to both fetus and
mother. Although the risks to the fetus of natalizu-
mab exposure appear low and reversible,7 further evi-
dence is required, particularly long-term data on
children exposed in utero. Careful counselling at
the time of natalizumab initiation in women of child-
bearing age is imperative.
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